[금일 제약업계 주요기사]Celltrion, Corona 19 Antibody Treatment Phase 2 Results… Seegene, global business expansion’Start’, etc.

【Youth Daily】 A major issue in the pharmaceutical industry on the 5th is the news that Celltrion will release the results of the Phase 2 clinical trial of the Corona 19 antibody treatment’Rekkironaju’ (CT-P59) on the 13th of this month.

SK Chemicals announced that it will expand partnerships with Lily of Korea for osteoporosis treatment’Posteo’ and migraine prevention treatment’Amgellity’, and the Ministry of Food and Drug Safety cautions that’Chloroquine’ has not proven effective in treating and preventing COVID-19. did.

Pameksin and Syntekabio will participate in the’JP Morgan Healthcare Conference 2021′, which will be held online on the 11th to 14th, and Huons Golf Team took the first step of the 2021 season by recruiting Professor Soi Kim, who was ranked 27th in the 2020 season prize money ranking.

Ahn Kook Pharm started the new year by holding a non-face-to-face opening ceremony in 2021, and Huzel, who participates as a presenter at the JP Morgan Healthcare Conference for the second consecutive year, discusses ‘2020 achievements and 2025 vision’ through the’Emerging Markets’ track. Announce.

Seegene recruited President Lee Ho as the executive in charge of global sales and marketing to solidify its position in the global molecular diagnostics market that has been expanded to Corona 19, and i-Tech completed the payment of a paid-in capital increase to Songjeong Pharmaceutical, a vaccine and specialty drug distribution company. The acquisition was completed by securing a total 53% stake in management.

◆ Celltrion Corona 19 antibody treatment, Phase 2 clinical results released on the 13th of this month

The results of the Phase 2 clinical trial of Celltrion’s Corona 19 antibody treatment’Rekironaju’ (codename CT-P59) will be released for the first time on the 13th of this month.

Celltrion decided to participate in the ‘2021 High1 New Drug Development Symposium’ hosted by the Korean Pharmacopoeia and announce the results of the global phase 2 clinical trial of Rekkirona.

Earlier, Celltrion applied for conditional approval from the Korean Food and Drug Administration after completing Phase 2 of the global clinical trial of Rekirona, but did not disclose detailed clinical data.

This is because, at the request of the Ministry of Food and Drug Safety, taking into account the public’s focus on the treatment for Corona 19, detailed data has been agreed to be closed until further instructions.

However, even though the introduction of the domestic COVID-19 treatment was made visible, the clear clinical result was decided to be announced early as concerns spread that there was no doubt.

◆ SK Chemicals strengthens partnership with Lily Korea… “Increase cooperation between Posteo and Amgelity”

SK Chemicals expands partnership with Lily Korea’s osteoporosis treatment’Posteo’ and migraine prevention treatment’Amgellity’.

SK chemicals started co-promotion for POSEO in April 2018 at some semi-hospitals and clinics, and expanded its sales activities to all semi-hospitals the following year. Since June of last year, Amgelati has been conducting marketing and sales in general hospitals in cooperation with both companies, and SK Chemicals is in charge of clinics.

SK Chemicals and Lily Korea have built mutual trust and created positive synergy through the partnership between Amgelati and Posteo.Based on this, since January 1 of this year, the partnership between Amgelati and Posteo has been expanded to all hospitals and clinics. Decided to do.

◆ Ministry of Food and Drug Safety “Chloroquine, Corona 19 treatment and prevention effect cannot be proven”

The Ministry of Food and Drug Safety has proven that chloroquine is effective in preventing and treating Corona 19 in relation to the fact that false information containing “malaria treatment chloroquine can prevent and cure Corona 19” is spread on the market through social network services (SNS). It hasn’t been done, so you need to be careful about using it.

‘Chloroquine’ is a prescription medicine used to treat malaria. In the first half of last year, Korea, the United States, the United Kingdom, and the World Health Organization (WHO) recommended that chloroquine should not be used for preventive and therapeutic purposes, saying that the therapeutic benefit was not recognized for corona19 patients.

The European Medicines Agency (EMA) also warned that serious side effects such as heartbeat abnormalities occur after taking’chloroquine’ and evaluated that the possibility of nerve cell damage that can lead to liver and kidney disorders, seizures and hypoglycemia cannot be ruled out. .

The anti-inflammatory drug’Dexamethasone’, which is currently used in severely ill patients with Corona 19, can also worsen infection symptoms due to its immune suppression, so even if it is used for the treatment of Corona 19, you must follow the doctor’s consultation and prescription, the Ministry of Food and Drug Safety explained.

◆ Participated in’JP Morgan Healthcare Conference’ “Exporting core pipeline technology”

Pamexin will host’JP Morgan Healthcare Conference 2021′ to be held online on the 11th to 14th, and’BIO Partnering at JPM’ and’Biotech Showcase’ to be held online from 11 to 15th (Biotech Showcase 2021).

At this event, Pamexin will introduce its core technologies and pipelines such as Olinvacimab, PMC-403, PMC-402 and PMC-309 to multinational pharmaceutical companies, and discuss the possibility of joint research and technology transfer of substances.

◆ Syntekabio’s’JP Morgan Healthcare Conference’ participation… “Discussion of AI drug development platform performance”

Syntekabio, an AI-based drug development company, is officially invited to participate in the ’39th JP Morgan Healthcare Conference’ held online for four days from 11 to 14.

At this conference, Syntekabio will discuss its achievements to date and future collaboration plans, focusing on its own new drug pipeline, its own AI drug development platform technology, and genome precision medical service.

◆ Huons Golf Team recruits Kim Soi… “Complete the player composition for the 2021 season”

The Huons Golf Club, run by Huons, is taking a strong first step in the 2021 season by recruiting Soi Kim, who ranked 27th in the prize money rankings in the 2020 season.

Huons recruited Soi Kim (26) this year and officially launched the 2021 season golf team consisting of 4 players including Choi Min-kyung (28), Jeong Seul-gi (25), and Gong Mi-jeong (23).

◆ Ahn Kook Pharm holds the opening ceremony in 2021… Overcoming the corona crisis and making a leap forward

Ahn Kook Pharm holds the New Year 2021 opening ceremony non-face-to-face. The opening ceremony was conducted live online to participate in the government’s strong social distancing policy, and employees watch the ceremony online using their personal PC or mobile phone.

We also announced three management policies to achieve ‘2030 New Vision’ and overcome the crisis in the corona era, such as improving productivity through fair evaluation and compensation for work performance, improving the body as an organization that responds agilely, and activating communication using digital information.

◆ Huzel “2025 Vision·Three-Year Strategy Revealed at JP Morgan Healthcare Conference”

Huzel, who participates in the JPMorgan Healthcare Conference as a presenter for the second consecutive year, announced ‘2020 Achievements and 2025 Vision’ through the’Emerging Market’ track on the 13th at 9:30 pm (Korean time) Do it.

The company explained that it will also hold 1:1 meetings with major overseas institutional investors during the conference.

A large number of key executives and staff members attended the presentation, including CEO Ji-hoon Son, Vice President of Development Division Chang-jin Lee, and Ji-hye Noh, Executive Vice President of Communication Division.

◆ Seegene recruited Lee Ho, general manager of sales and marketing… Global business expansion’spurs’

Seegene recruited President Lee Ho as the general manager of global sales and marketing to solidify its position in the global molecular diagnostics market that has been expanded by Corona 19.

President Lee Ho is an expert who has focused on global market sales and marketing for more than 30 years, spanning four continents, including serving as the head of the US sales subsidiary, the French sales subsidiary, the Latin American region representative, and the Asian region representative at LG Electronics.

Seegene is in full swing to solidify its position as a global molecular diagnostics company that has achieved through the introduction of President Lee Ho.

Seegene, which is currently driving sales in the global market through 7 overseas subsidiaries and 60 agencies, plans to expand its global preoccupation opportunities from this year through more active corporate expansion and manpower investment.

◆ i-Tech completes acquisition of Songjung Pharm… “Entering the main trajectory of vaccine and prescription drug business”

I-Tech completed the payment of a paid-in capital increase for Songjung Pharm, a vaccine and prescription drug distribution company, and secured a 53% stake in management and completed the acquisition.

As a result, i-Tech has completed the establishment of a three-way partnership between its subsidiaries i-Tech H&D, Songjeong Pharm, and Dongwoo Tech to establish a vaccine and prescription drug distribution business system.

Company officials are expected to be able to quickly respond to the expanding market by establishing a collaboration system between Songjung Pharm, which has a long experience in vaccine distribution and delivery, and Dongwoo Tech, which possesses unique cold chain ICT technology and platform. To this end, it plans to actively support liquidity.

【Youth Daily = Reporter Ahn Sang-jun】